1 Super-Safe High-Yield Dividend King Stock to Buy Even if There's a Stock Market Sell-Off in 2026

Kimberly-Clark reported modest 2025 results with 1.7% organic sales growth (2.5% volume, -0.9% price), 36% gross margins, flat adjusted operating profit and adjusted EPS up 3.2%; it guided 2026 to ~2% organic growth, flat adjusted EPS and a mid-to-high single-digit constant-currency increase in adjusted operating profit. The company raised its dividend for the 54th consecutive year (yield ~5%) and is pursuing a major acquisition of Kenvue expected to close H2 2026, forecasting $2.1 billion in annual synergies (including $1.9 billion cost synergies) and EPS accretion by year two, while executing a multiyear restructuring under its Powering Care plan.

Analysis

Market structure: KMB’s acquisition of KVUE re-shapes the consumer staples map by combining high-margin consumer health brands with low-margin paper products. Winners are scale suppliers (pulp, packaging) and private-label challengers that force price discipline; losers include smaller regional tissue and niche feminine-care players as KMB targets share gains. Expect modest pricing pressure near-term (volumes +2–3%, price -0.5 to -1.5%) as KMB pursues cross-sell and cost synergies; FX and input costs (pulp, energy) are key supply-side levers.

Risk assessment: Tail risks include synergy shortfalls >25% (wipes sizable portion of the $2.1B target), integration-related goodwill impairment, or leverage rising above ~3.5x net debt/EBITDA forcing dividend re-think. Immediate risk (days): muted sentiment and options vol uptick; short-term (3–12 months): guidance resets and deal-close execution; long-term (2–4 years): realized EPS accretion by year two post-close (H2 2028) or structural market-share gains. Hidden dependency: retailer shelf economics and category co-promotion execution (failure delays accretion).

Trade implications: Direct play: selective long KMB for income (target 2–3% portfolio weight) with defined hedges; use covered-call overlays (6-month calls 8–12% OTM) to raise yield now. Pair trade: long KMB vs short PG (Procter & Gamble) dollar-neutral for 6–24 months to capture re-rate if integration shows early wins; size short ~60% of long to neutralize category beta. Options: buy 24–30 month bull-call spread (buy near-ATM, sell 35–45% OTM) to capture H2 2028 accretion while capping premium; buy 12-month 10% OTM puts (0.5% position) as insurance.

Key Decisions for Investors

• Establish a 2–3% long position in KMB for a 3–5 year income hold (target total yield ~5%), add on >10% pullback, and trim/exit if dividend coverage (FCF/dividend) falls below 1.0x or net debt/EBITDA >3.5x.
• Implement a hedged yield overlay: buy KMB stock and sell 6-month covered calls 8–12% OTM to boost rolling income; roll every 3–6 months or stop if stock rallies >20% from entry.
• Deploy a volatility/catalyst spread: buy a 24–30 month bull-call spread on KMB (buy near-ATM LEAP, sell 35–45% OTM) sized 0.5–1% notional to capture expected EPS accretion by H2 2028; finance with short-dated call sales where appropriate.
• Run a dollar-neutral pair: long KMB (1.0) / short PG (0.6) for 6–24 months to exploit relative valuation (KMB ~13x forward vs PG premium) and potential re-rating if integration progresses; reassess at each quarterly earnings or on synergy updates.
• Set hard risk triggers to exit/hedge: if KMB reports synergy realization <50% of plan at the first post-close update (expected within 12 months of close) or announces dividend freeze/cut, reduce exposure by 100% within 5 trading days.